Chiron Real Estate (XRN) Stock Overview
A net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 4/6 |
XRN Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Chiron Real Estate Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.27 |
| 52 Week High | US$39.93 |
| 52 Week Low | US$29.05 |
| Beta | 1.14 |
| 1 Month Change | 3.41% |
| 3 Month Change | 12.67% |
| 1 Year Change | 7.56% |
| 3 Year Change | -19.42% |
| 5 Year Change | -49.91% |
| Change since IPO | -98.49% |
Recent News & Updates
Narrative Update • Jun 17
XRN: Future Returns Will Hinge On Dilutive Shift To Senior Housing
The analyst price target for Chiron Real Estate has been reset from $33.05 to $14.32 as analysts factor in the expected earnings dilution and limited near term performance markers related to the company's ongoing shift toward senior housing operations. Analyst Commentary Recent Street research around Chiron Real Estate centers on the company’s pivot toward senior housing operations, with several bearish analysts highlighting the potential for earnings dilution and limited near term visibility on performance.
Narrative Update • Jun 03
XRN: Senior Housing Pivot And Preferred Capital Are Expected To Unlock Upside
Analysts have lifted their average price target on Chiron Real Estate to $39 from $33, citing the company's pivot toward higher growth SHOP community acquisitions and the potential value in its legacy portfolio, despite recent dividend cuts and withdrawn guidance. Analyst Commentary Recent Street research shows a split view on Chiron Real Estate, but the latest price target move to US$39 from US$33 highlights that some bullish analysts see room for upside if the current pivot is executed well.Recent updates
Narrative Update • Jun 17
XRN: Future Returns Will Hinge On Dilutive Shift To Senior Housing
The analyst price target for Chiron Real Estate has been reset from $33.05 to $14.32 as analysts factor in the expected earnings dilution and limited near term performance markers related to the company's ongoing shift toward senior housing operations. Analyst Commentary Recent Street research around Chiron Real Estate centers on the company’s pivot toward senior housing operations, with several bearish analysts highlighting the potential for earnings dilution and limited near term visibility on performance.Narrative Update • Jun 03
XRN: Senior Housing Pivot And Preferred Capital Are Expected To Unlock Upside
Analysts have lifted their average price target on Chiron Real Estate to $39 from $33, citing the company's pivot toward higher growth SHOP community acquisitions and the potential value in its legacy portfolio, despite recent dividend cuts and withdrawn guidance. Analyst Commentary Recent Street research shows a split view on Chiron Real Estate, but the latest price target move to US$39 from US$33 highlights that some bullish analysts see room for upside if the current pivot is executed well.Narrative Update • May 12
XRN: Senior Housing Shift And Preferred Issuance Will Support Future Upside
Analysts have lowered their price target on Chiron Real Estate to $46 from $50, citing updated assumptions that include slightly slower revenue growth, a higher discount rate, and a lower future P/E multiple, partially offset by a modestly higher profit margin outlook. Analyst Commentary Recent Street research paints a mixed picture, but there are still several clear positives that bullish analysts are pointing to as they reassess Chiron Real Estate's outlook and valuation framework.Narrative Update • Apr 23
XRN: Active Adult And Senior Housing Focus Will Support Future Upside
Analysts have raised their price target on Chiron Real Estate to $42 from $40, citing the company’s planned investments in active adult and senior housing, where they see a more attractive return profile than medical offices. Analyst Commentary Bullish analysts highlight Chiron Real Estate's decision to allocate capital toward active adult and operating senior housing as a key reason for lifting the price target to $42.Seeking Alpha • Apr 17
Chiron Real Estate: From High-Teens To Sub-10x FFO, A Rebound Case
Summary Chiron Real Estate is rated a 'buy' due to a significant margin of safety versus intrinsic value and a compelling 8.5% monthly dividend yield. XRN's portfolio is diversified across healthcare assets, with manageable tenant and geographic concentration; no major refinancing risk exists until after 2027. At $35.24, XRN trades at ~9x FFO, well below its historical multiple and 32% below intrinsic value, offering a conservative total return expectation of 10.6%. High leverage increases sensitivity to interest rates, but management alignment and recent insider buying reinforce conviction in undervaluation and future upside. Read the full article on Seeking AlphaNarrative Update • Apr 08
XRN: Future Returns Will Depend On Active Adult And Senior Housing
Analysts have lifted their price target on Chiron Real Estate to $42 from $40, citing the company’s expanding push into active adult and senior housing. They view this segment as offering a more attractive return profile than medical offices.Narrative Update • Mar 25
XRN: Active Adult And Senior Housing Shift Will Support Stronger Future Upside
Analysts have lifted their price target on Chiron Real Estate to $42 from $40, citing updated valuation work that reflects revised fair value and cash flow assumptions, along with the company’s planned push into active adult and senior housing, which they view as offering a more attractive return profile than medical offices. Analyst Commentary Recent research shows bullish analysts becoming more constructive on Chiron Real Estate after the company outlined plans to invest in active adult and operating senior housing alongside its existing medical office exposure.Narrative Update • Mar 09
XRN: Future Outlook Will Hinge On Active Adult And Senior Housing Execution
Analysts have lifted their price target on Chiron Real Estate to $42 from $40, citing the company’s planned investments in active adult and senior housing as a key driver behind the updated view. Analyst Commentary Analysts framing the new US$42 price target point to Chiron’s plans in active adult and senior housing as a potential support for earnings and asset values, especially compared with its existing focus on medical offices.
Narrative Update • Feb 23
GMRE: Lower Discount Rate And Name Change Will Support Bullish Outlook
Analysts have nudged their price target on Global Medical REIT higher, citing updated assumptions for fair value to $40.86, a slightly lower discount rate of 9.28%, and modestly adjusted estimates for revenue growth, profit margin and future P/E. What's in the News Effective February 23, 2026, Global Medical REIT Inc.Narrative Update • Feb 08
GMRE: Future Outlook Will Balance Rebranding Plans And Steady Earnings Assumptions
Analysts have kept their fair value target for Global Medical REIT steady at US$35.00, citing minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions that largely offset one another. What's in the News Global Medical REIT plans to change its corporate name to Chiron Real Estate Inc., effective February 23, 2026 (Key Developments).Narrative Update • Jan 25
GMRE: Future Outlook Will Balance Profit Margin Hopes And Muted Buyback Activity
Analysts have adjusted their price target for Global Medical REIT to US$35.00, reflecting updated assumptions that include a lower discount rate, slightly higher revenue growth, improved profit margin expectations, and a reduced future P/E multiple. What's in the News From August 12, 2025 to September 30, 2025, Global Medical REIT reported no share repurchases under its buyback program, with 0 shares bought for US$0 million, representing 0% of shares.Narrative Update • Jan 11
GMRE: Higher Future P/E Assumptions Will Support A More Optimistic Outlook
Analysts now set their price target for Global Medical REIT at US$40.25, down from US$44.84, reflecting updated assumptions for slower revenue growth, slightly higher discount rates and more modest profit margins, alongside a higher future P/E multiple in their models. What's in the News Buyback program update: from August 12, 2025 to September 30, 2025 the company repurchased 0 shares, representing 0%, for US$0 million.Narrative Update • Dec 26
GMRE: Future Outlook Will Balance Higher Fair Value And Cautious Profit Assumptions
Analysts have raised their price target on Global Medical REIT sharply from 7.50 dollars to 35.00 dollars, citing a higher long term fair value framework, despite slightly higher discount rates and more conservative assumptions for revenue growth, profit margins, and future valuation multiples. What's in the News Global Medical REIT reported that between August 12, 2025 and September 30, 2025, it repurchased 0 shares for 0 dollars, completing its previously announced buyback program without any actual share repurchases (Key Developments).Narrative Update • Dec 12
GMRE: Reverse Split And Higher Multiple Will Support Stronger Future Upside
Analysts have raised their price target on Global Medical REIT from approximately $12 to about $57 per share, citing an updated fair value assessment that offsets modestly lower revenue growth and profit margin expectations, along with a slightly richer future earnings multiple. What's in the News Global Medical REIT amended its charter under Maryland law to implement a 1 for 5 reverse stock split, consolidating every five existing common shares into one new share with a par value of $0.005.Narrative Update • Sep 23
Discounted Outpatient Properties Will Unlock Healthcare Real Estate Potential
Despite a decrease in net profit margin and a higher future P/E multiple, the consensus analyst price target for Global Medical REIT has surged from $8.97 to $44.84. What's in the News Announced a 1-for-5 reverse stock split, consolidating every five shares into one and paying cash in lieu for fractional shares.New Narrative • May 30
Outpatient Property Acquisitions Will Fuel US Healthcare Demand
Strategic acquisitions of high-quality outpatient properties and diversified hospital-affiliated tenants align with demographic healthcare trends, supporting long-term revenue and asset growth.Seeking Alpha • Apr 16
Global Medical REIT: A Buying Opportunity Emerges In The 7.5% Preferred Shares (Rating Upgrade)
Summary Global Medical REIT is a triple-net healthcare REIT focused on medical office buildings and inpatient rehabilitation facilities. The REIT's preferred shares have recently dipped below par value, allowing investors to lock in an attractive dividend yield just as the Fed is about to renew its policy normalization. Preferred dividends remain well covered in terms of AFFO. Preferred equity likewise enjoys a substantial common equity cushion. The REIT's common stock remains attractive, as its 2025 AFFO outlook shows it will be able to maintain its double-digit dividend even as it addresses debt maturities. The uncertain timing of future Fed rate cuts is a key risk to consider. Read the full article on Seeking AlphaSeeking Alpha • Jan 27
Global Medical REIT: Attractive Valuation Despite Refinancing Headwinds
Summary Global Medical REIT primarily invests in outpatient medical facilities, with the company's largest markets being Texas, Florida, and Ohio. The REIT should generate marginally higher AFFO in 2025 thanks to rent indexation, fading impact from the Steward Health Care bankruptcy, and portfolio growth. The company's debt is 81% fixed-rate at 3.18%, but low average maturity implies rising interest costs will weigh on AFFO growth in 2025-2026. The company's valuation remains attractive on an AFFO-multiple and enterprise-level basis. Key risks to consider include declining occupancy, low average debt maturity, and additional tenant bankruptcies in the future. Read the full article on Seeking AlphaSeeking Alpha • Sep 24
Global Medical REIT's Underwriting Is Demonstrated To Be Effective
Summary Global Medical REIT (GMRE) trades at a significant discount with a P/AFFO under 11X, compared to the healthcare REIT sector mean of 15.7X. GMRE's strong underwriting and recent lease agreements ensure stable forward cashflows, despite market concerns over Steward's bankruptcy. GMRE's superior acquisition strategy, transparency, and investor alignment have enabled it to grow AFFO/share even during challenging periods for healthcare REITs. With a fair value estimate of 15X AFFO, GMRE shares have a potential upside of 38% from the current price, reflecting asset quality and growth. Read the full article on Seeking AlphaSeeking Alpha • Aug 11
Global Medical REIT: Stability Across The Board, But More Is Needed To Be Bullish
Summary Q2, 2024 earnings results for Global Medical showed a decrease in FFO and AFFO compared to the prior-year quarter. The major driver for this was the relatively recently conducted dispositions, which quite naturally have imposed a drag on the top line. In this quarter, however, we can see how GMRE has started to deploy this capital at higher cap rates, thus aiming for a positive spread capture. Yet, to secure more meaningful growth and normalize the AFFO payout, GMRE has to rely on equity issuance, which will start to make sense when the multiple becomes a bit higher. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Global Medical: The Yield Is Not Too Good To Be True
Summary Global Medical's portfolio consists of 185 properties across 34 states, with strong rent coverage and tenant diversification. GMRE pays a high dividend yield of 9.53% and the payout ratio is 92.3%, but I think a dividend cut is unlikely. Demand for medical services is resilient and the REIT has manageable debt levels to take advantage of it in the long term. The shares are now trading at a significant discount to NAV, but the market has assigned a premium to it in the past. Read the full article on Seeking AlphaSeeking Alpha • May 23
Global Medical: The 7.6% Preferred Yield Trumps The Common
Summary Global Medical REIT Inc. experienced a slight decline in revenues and occupancy levels in Q1-2024. The company's growth strategy has stalled, but it still yields a whopping 9.6%. We look at the dividend safety of the common shares and also go over why we don't own the safer preferreds yielding 7.6%. Read the full article on Seeking AlphaSeeking Alpha • May 09
Global Medical REIT: Better Q1 Than Expected, But Still A Cautious Stance
Summary While I have been covering Global Medical since early 2019 and it is still my only healthcare REIT in the portfolio, a couple of quarters ago I turned bearish here. The reason for this is very minor margin of safety when it comes to GMRE's ability to accommodate the current dividend. However, the recently announced Q1, 2024 results showed an improved picture, where there was a clear stability in the AFFO generation and some attractive moves in the M&A space. While the profile has indeed improved, I still remain cautious and I am certainly not adding more or reinvesting the dividends here. In this article, I elaborate on Q1, 2024, and explain why I have decided to maintain a hold rating. Read the full article on Seeking AlphaSeeking Alpha • Mar 09
Global Medical REIT Offers A 9.3% Dividend Yield And 7.6% On The Preferreds
Summary Global Medical REIT owns 185 healthcare facilities leased to physicians and healthcare-related groups. The REIT's tenants appear to be well-managed, with a strong rent coverage ratio. Global Medical's FFO and AFFO performance remains satisfying, with a comfortable dividend coverage ratio for preferred shares. Read the full article on Seeking AlphaSeeking Alpha • Feb 29
Global Medical REIT: Nothing Promising After Q4 Results, Still A Hold
Summary Global Medical REIT just circulated its Q4 2023 earnings, which indicate stability across the board. Yet, the market is clearly punishing the stock. In this article, I synthesize the key messages from the Q4 2023 results and justify why I still consider GMRE a hold. Read the full article on Seeking AlphaShareholder Returns
| XRN | US Health Care REITs | US Market | |
|---|---|---|---|
| 7D | 6.3% | 9.2% | -2.5% |
| 1Y | 7.6% | 37.6% | 19.0% |
Return vs Industry: XRN underperformed the US Health Care REITs industry which returned 37.6% over the past year.
Return vs Market: XRN underperformed the US Market which returned 19% over the past year.
Price Volatility
| XRN volatility | |
|---|---|
| XRN Average Weekly Movement | 4.8% |
| Health Care REITs Industry Average Movement | 4.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XRN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XRN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 30 | Mark Decker | www.chironre.com |
Chiron Real Estate Inc. is a net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. Chiron Real Estate Inc. was established on March 18, 2011, incorporated in Maryland and is based in Bethesda, Maryland.
Chiron Real Estate Inc. Fundamentals Summary
| XRN fundamental statistics | |
|---|---|
| Market cap | US$509.81m |
| Earnings (TTM) | -US$14.97m |
| Revenue (TTM) | US$151.53m |
3.3x
P/S Ratio-33.0x
P/E RatioIs XRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRN income statement (TTM) | |
|---|---|
| Revenue | US$151.53m |
| Cost of Revenue | US$0 |
| Gross Profit | US$151.53m |
| Other Expenses | US$166.50m |
| Earnings | -US$14.97m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -9.88% |
| Debt/Equity Ratio | 127.4% |
How did XRN perform over the long term?
See historical performance and comparisonDividends
5.2%
Current Dividend Yield96%
Payout RatioDoes XRN pay a reliable dividends?
See XRN dividend history and benchmarks| Chiron Real Estate dividend dates | |
|---|---|
| Ex Dividend Date | Jun 22 2026 |
| Dividend Pay Date | Jul 17 2026 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 17 days |
Does XRN pay a reliable dividends?
See XRN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 19:23 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chiron Real Estate Inc. is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Mehta | Alliance Global Partners |
| David Rodgers | Baird |
| Amanda Sweitzer | Baird |